Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastases

NAActive, not recruitingINTERVENTIONAL

Enrollment

399

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions

Metastatic Tumors

Interventions

RADIATION

Stereotactic Ablative Body Radiotherapy

The total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks

Trial Locations (1)

BC Cancer, Prince George

All Listed Sponsors

lead

British Columbia Cancer Agency

OTHER

NCT02933242 - Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastases | Biotech Hunter | Biotech Hunter